Chlamydia is preventable through a combination of barrier use during sex, routine screening, and making sure sexual partners get treated. No single strategy eliminates risk entirely, but layering several approaches together offers strong protection. Here’s what works and how to put it into practice.
Condoms Reduce Transmission Risk
Latex and polyurethane condoms, used consistently and correctly, reduce the risk of chlamydia transmission by acting as a physical barrier to the genital secretions that carry the bacteria. The CDC confirms that epidemiologic studies comparing infection rates among condom users and nonusers show clear protective effects against chlamydia, gonorrhea, and trichomoniasis.
The key word is “consistently.” Using a condom for some encounters but not others leaves significant gaps in protection. Chlamydia can be transmitted through vaginal, anal, and oral sex, so condoms or other barriers are relevant for all three. For oral sex, dental dams or condoms provide a barrier, though they’re used far less often in practice. Internal (female) condoms are another option that can be inserted before sex begins, giving the receptive partner more control over barrier use.
Why Younger Women Face Higher Risk
Biology plays a role in who gets infected. The cervix in younger women commonly has a condition called cervical ectopy, where a type of cell that lines the inner cervical canal is also present on the outer surface. These cells are more vulnerable to chlamydia than the tougher cells that typically cover the outer cervix. In a study of women with an average age of about 20, chlamydia was detected in 37% of those with cervical ectopy compared to 22% of those without. That difference held up even after accounting for other risk factors.
Cervical ectopy is a normal physiological process, not a medical problem. It’s more common during adolescence, pregnancy, and with hormonal contraceptive use. It does, however, help explain why chlamydia rates are highest in women under 25 and why screening guidelines focus heavily on this age group.
Screening Catches What Prevention Misses
Because chlamydia often causes no symptoms at all, regular testing is one of the most important prevention tools available. You can carry and spread the infection for months without knowing it. Screening guidelines from the CDC recommend:
- Women under 25: Annual screening if sexually active
- Women 25 and older: Annual screening if at increased risk (new or multiple partners, for example)
- Pregnant women under 25: Screening during pregnancy
- Men who have sex with men: At least annually at all sites of contact (urethra, rectum), regardless of condom use. Every 3 to 6 months if on PrEP, living with HIV, or if either partner has multiple partners
- Transgender and gender diverse individuals: Screening based on anatomy. Anyone with a cervix under 25 should be screened annually, and those over 25 should be screened if at increased risk
- People with HIV: At first HIV evaluation and at least annually after that
There are no routine screening recommendations for heterosexual men at low risk, though testing in high-prevalence settings like STI clinics or correctional facilities is sometimes offered.
When to Test After Exposure
If you think you’ve been exposed, timing matters. Testing too early can produce a false negative. Chlamydia is detectable by a urine sample or swab (vaginal, rectal, or throat) as early as one week after exposure in most cases. Waiting two weeks catches nearly all infections. Testing before one week often misses the bacteria before they’ve multiplied enough to register.
Treating Partners Prevents Reinfection
One of the biggest gaps in chlamydia prevention is what happens after someone tests positive. Treatment with antibiotics clears the infection, but if your sexual partner isn’t also treated, reinfection is likely. The numbers are striking: in a study of adolescents and young adults retested within a year of treatment, 22% tested positive for chlamydia again.
Expedited partner therapy, where your healthcare provider gives you a prescription or medication to pass along to your partner without requiring them to come in for their own visit, reduces reinfection rates compared to simply telling your partner to go get tested on their own. The American College of Obstetricians and Gynecologists supports this approach when a partner is unable or unwilling to seek care independently. It’s legal in most U.S. states, though rules vary.
After treatment, retesting is recommended at about three months to catch reinfection early. This is separate from a “test of cure,” which confirms the original infection cleared. Retesting at three months is about catching new exposure, which is common because the circumstances that led to the first infection often haven’t changed.
Post-Exposure Antibiotics for High-Risk Groups
A newer prevention strategy involves taking an antibiotic within 72 hours after a high-risk sexual encounter. The CDC issued guidelines in 2024 supporting this approach for men who have sex with men and transgender women. In clinical trials, this post-exposure approach reduced chlamydia infections by 70% to nearly 90% depending on the study.
There’s an important limitation. A trial in cisgender women in Kenya found no significant reduction in bacterial STIs with this same approach. The reasons aren’t entirely clear, but may relate to differences in how the antibiotic reaches vaginal and cervical tissue versus rectal or urethral tissue. For now, the CDC recommends this strategy specifically for men who have sex with men and transgender women, not for cisgender women or heterosexual men.
Mutual Monogamy and Reducing Partners
Being in a mutually monogamous relationship with a partner who has tested negative is one of the most effective ways to avoid chlamydia. The operative word is “tested.” Since chlamydia can be completely silent for long periods, assuming a partner is negative based on the absence of symptoms isn’t reliable. Getting tested together before stopping condom use closes that gap.
Reducing the number of sexual partners also lowers risk in straightforward mathematical terms: fewer partners means fewer potential exposures. This doesn’t mean any specific number is “safe” or “unsafe.” One untreated partner can transmit chlamydia just as easily as several. But in combination with condom use and screening, fewer partners reduces overall probability.
Vaccines Are Still in Development
There is currently no approved vaccine for chlamydia, but development is further along than many people realize. One candidate based on a key protein on the surface of the chlamydia bacterium completed early-stage human trials and proved safe while generating a strong immune response, including antibodies in vaginal and urethral tissue where the infection takes hold. A newer vaccine using mRNA technology (the same platform behind some COVID-19 vaccines) entered a mid-stage clinical trial in March 2025, with results expected by early 2028. A working vaccine would be transformative, but it’s still years away from potential availability.